Drugs / QLS31904
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05461287 | Sep 2022 → Sep 2024 | neoplasm | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS31904 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05461287 ↗ |
| Modality | Protein / enzyme biologic | “bi-specific recombinant protein construct” NCT05461287 ↗ |
| Route | Intravenous | “QLS31904 q2w/q3w intravenous use” NCT05461287 ↗ |